Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

[1]  Jens Meiler,et al.  PyIR: a scalable wrapper for processing billions of immunoglobulin and T cell receptor sequences using IgBLAST , 2020, BMC Bioinformatics.

[2]  D. Fremont,et al.  Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2 , 2020, Cell Host & Microbe.

[3]  J. Dye,et al.  Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.

[4]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[5]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[6]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[7]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[8]  Lisa E. Gralinski,et al.  Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals , 2020, bioRxiv.

[9]  X. Xie,et al.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.

[10]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals , 2020, bioRxiv.

[11]  Cinque S. Soto,et al.  Integrated technology platform for accelerated discovery of antiviral antibody therapeutics , 2020, bioRxiv.

[12]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[13]  D. Burton,et al.  Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model , 2020, bioRxiv.

[14]  J. Mascola,et al.  Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus , 2020, PloS one.

[15]  F. Gao,et al.  A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.

[16]  C. Hillyer,et al.  Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.

[17]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[18]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[19]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[20]  J. Crowe,et al.  Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization , 2020, Immunity.

[21]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[22]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[23]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[24]  Tristan Bepler,et al.  Topaz-Denoise: general deep denoising models for cryoEM and cryoET , 2019, Nature Communications.

[25]  Barney S. Graham,et al.  Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD , 2019, Cell Reports.

[26]  J. Sidney,et al.  Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection , 2019, Cell.

[27]  Y. Kawaoka,et al.  Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection , 2019, Journal of Virology.

[28]  James E. Crowe,et al.  High frequency of shared clonotypes in human B cell receptor repertoires , 2019, Nature.

[29]  Karlynn E. Neu,et al.  An Efficient Method to Generate Monoclonal Antibodies from Human B Cells. , 2018, Methods in molecular biology.

[30]  G. Gibson,et al.  Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion , 2018, Nature Communications.

[31]  Linqi Zhang,et al.  Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein , 2018, Cell Reports.

[32]  P. Niu,et al.  Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient , 2018, The Journal of infectious diseases.

[33]  Robert J. Fischer,et al.  Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape , 2018, Journal of Virology.

[34]  Jianmin Wang,et al.  Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset , 2017, The Journal of infectious diseases.

[35]  David J. Fleet,et al.  cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.

[36]  T. Pierson,et al.  Enhancing dengue virus maturation using a stable furin over-expressing cell line. , 2016, Virology.

[37]  R. Baric,et al.  Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus , 2015, Proceedings of the National Academy of Sciences.

[38]  Yuansheng Yang,et al.  Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells , 2015, mAbs.

[39]  D. Dimitrov,et al.  Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies , 2014, Journal of Virology.

[40]  K. Yuen,et al.  Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein , 2014, Science Translational Medicine.

[41]  R. Baric,et al.  Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution , 2014, Proceedings of the National Academy of Sciences.

[42]  Vineet D. Menachery,et al.  Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus , 2013, Proceedings of the National Academy of Sciences.

[43]  J. Yewdell,et al.  Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection , 2011, The Journal of experimental medicine.

[44]  R. Baric,et al.  Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge , 2008, Journal of Virology.

[45]  Thomas Walz,et al.  Negative Staining and Image Classification – Powerful Tools in Modern Electron Microscopy , 2004, Biological Procedures Online.

[46]  D. Dimitrov,et al.  Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies , 2007, Proceedings of the National Academy of Sciences.

[47]  Jaap Goudsmit,et al.  Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.

[48]  David N Mastronarde,et al.  Automated electron microscope tomography using robust prediction of specimen movements. , 2005, Journal of structural biology.

[49]  T. Kuiken,et al.  Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets , 2004, The Lancet.

[50]  Wenhui Li,et al.  Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Ralph S. Baric,et al.  Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus , 2003, Proceedings of the National Academy of Sciences of the United States of America.